Brukinsa won approval for another blood cancer last month. ArQule's lead product candidate is a BTK inhibitor, ARQ-531, designed for heavily pretreated patients with leukemias and lymphomas ...

If BTK inhibitors work the way scientists think they do, they might help people with progressive MS. But that’s something researchers are still looking into. We’re also starting to explore ...

“Our work in oncology is founded on respect ... an investigational Bruton’s tyrosine kinase (BTK) inhibitor, being studied in the United States by ONO. “BTK is a key regulator of the ...

The BTK inhibitors market has experienced significant dynamics driven by advancements in oncology and autoimmune disease treatments. One of the primary drivers of the BTK inhibitors market is the ...

Jaypirca belongs to a class of medications called Bruton’s tyrosine kinase (BTK) inhibitors, which block a protein critical ...

Shandong New Time Pharmaceutical Co. Ltd. has disclosed compounds acting as Bruton tyrosine kinase (BTK) inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.

Roche has presented more data from a Phase II study of its Bruton’s tyrosine kinase (BTK) inhibitor after long-term data ...

The French pharma said it will pay $100 per share in cash for San Francisco-based Principia, which specialises in Bruton’s kinase (BTK) inhibitor drugs, after the deal was unanimously agreed by ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...